10
Participants
Start Date
April 12, 2013
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
BAROSTIM NEO System and Medical Management
"Experimental: Device and Medical Management~Subjects have been implanted with the BAROSTIM NEO System and receive optimal medical management, including drugs to be determined by the subject's physician. Drug types include: Loop Diuretics; Thiazide Diuretics; Potassium-sparing Diuretics; Aldosterone receptor blockers; Beta-blockers; Beta-blockers with intrinsic sympathomimetic activity; Combined alpha- and beta-blockers; ACE inhibitors; Angiotensin II antagonists; Calcium channel blockers- non-Dihydropyridines; Calcium channel blockers- Dihydropyridines; Alpha1-blockers; Central alpha2-agonists and other centrally acting drugs; Direct vasodilators."
Allegheny General Hospital, Pittsburgh
George Washington University, Washington D.C.
Florida Hospital, Orlando
Tampa General Hospital, Tampa
Michigan CardioVascular Institute, Saginaw
Cardiac and Vascular Research Center of Northern Michigan, Petoskey
Aspirus Wausau Hospital, Wausau
Cardiovascular Institute of the South, Houma
Arizona Heart Rhythm Research Center, Phoenix
University Medical Center of Southern Nevada, Las Vegas
University of Southern California, Los Angeles
Lead Sponsor
CVRx, Inc.
INDUSTRY